CN100497333C - 用于治疗神经紊乱的二氢苯并二氮杂-2-酮衍生物 - Google Patents

用于治疗神经紊乱的二氢苯并二氮杂-2-酮衍生物 Download PDF

Info

Publication number
CN100497333C
CN100497333C CNB038065452A CN03806545A CN100497333C CN 100497333 C CN100497333 C CN 100497333C CN B038065452 A CNB038065452 A CN B038065452A CN 03806545 A CN03806545 A CN 03806545A CN 100497333 C CN100497333 C CN 100497333C
Authority
CN
China
Prior art keywords
phenyl
pyridin
methyl
trifluoromethyl
dihydrobenzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038065452A
Other languages
English (en)
Chinese (zh)
Other versions
CN1633430A (zh
Inventor
G·亚当
E·格斯奇
J·维希曼
T·J·沃特林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1633430A publication Critical patent/CN1633430A/zh
Application granted granted Critical
Publication of CN100497333C publication Critical patent/CN100497333C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB038065452A 2002-02-06 2003-01-28 用于治疗神经紊乱的二氢苯并二氮杂-2-酮衍生物 Expired - Fee Related CN100497333C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02002012.9 2002-02-06
EP02002012 2002-02-06

Publications (2)

Publication Number Publication Date
CN1633430A CN1633430A (zh) 2005-06-29
CN100497333C true CN100497333C (zh) 2009-06-10

Family

ID=27675598

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038065452A Expired - Fee Related CN100497333C (zh) 2002-02-06 2003-01-28 用于治疗神经紊乱的二氢苯并二氮杂-2-酮衍生物

Country Status (30)

Country Link
US (1) US6949542B2 (https=)
EP (1) EP1474416B1 (https=)
JP (1) JP4077411B2 (https=)
KR (1) KR20040081486A (https=)
CN (1) CN100497333C (https=)
AR (1) AR038481A1 (https=)
AT (1) ATE374196T1 (https=)
AU (1) AU2003205695B8 (https=)
BR (1) BR0307474A (https=)
CA (1) CA2474219C (https=)
DE (1) DE60316538T2 (https=)
DK (1) DK1474416T3 (https=)
ES (1) ES2294264T3 (https=)
GT (1) GT200300028A (https=)
HR (1) HRP20040678A2 (https=)
IL (1) IL163102A (https=)
MX (1) MXPA04007516A (https=)
MY (1) MY176608A (https=)
NO (1) NO327697B1 (https=)
NZ (1) NZ534122A (https=)
PA (1) PA8565901A1 (https=)
PE (1) PE20031011A1 (https=)
PL (1) PL372425A1 (https=)
PT (1) PT1474416E (https=)
RU (1) RU2315764C2 (https=)
SI (1) SI1474416T1 (https=)
TW (1) TWI326599B (https=)
UY (1) UY27654A1 (https=)
WO (1) WO2003066623A1 (https=)
ZA (1) ZA200406032B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE261945T1 (de) 1999-10-15 2004-04-15 Hoffmann La Roche Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
ES2293287T3 (es) * 2003-07-25 2008-03-16 F. Hoffmann-La Roche Ag Combinacion de antagonista de mglur2 y de inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos.
JP5048675B2 (ja) 2005-09-27 2012-10-17 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ２アンタゴニストとしてのオキサジアゾリルピラゾロ−ピリミジン類
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
ES2369866T3 (es) * 2007-04-19 2011-12-07 F. Hoffmann-La Roche Ag Derivados de dihidro-benzo[b][1,4]diazepin-2-ona-sulfonamida.
CN102083799B (zh) 2007-08-27 2013-10-16 霍夫曼-拉罗奇有限公司 用作fxr激动剂的苯并咪唑衍生物
CN101801930B (zh) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
PL2200985T3 (pl) 2007-09-14 2011-12-30 Ortho Mcneil Janssen Pharmaceuticals Inc 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JP5693452B2 (ja) 2008-08-04 2015-04-01 シーエイチディーアイ ファウンデーション，インコーポレーテッド 特定のキヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
TWI481601B (zh) 2009-08-21 2015-04-21 Otsuka Pharma Co Ltd 含氮化合物及藥學組成物
US8796447B2 (en) 2009-08-21 2014-08-05 Otsuka Pharmaceutical Co., Ltd. Process for producing benzo[B][1,4]diazepine-2,4-dione compound
CA2787365A1 (en) 2010-01-25 2011-07-28 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CA2834548C (en) 2011-04-28 2021-06-01 The Broad Institute, Inc. Inhibitors of histone deacetylase
CA2847247C (en) * 2011-08-29 2019-10-15 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
KR20140072037A (ko) 2011-08-30 2014-06-12 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
EP2877444B1 (en) 2012-07-27 2020-09-02 The Broad Institute, Inc. Inhibitors of histone deacetylase
CN104736140A (zh) 2012-10-23 2015-06-24 霍夫曼-拉罗奇有限公司 用于治疗自闭症的mGlu2/3拮抗剂
US9914717B2 (en) 2012-12-20 2018-03-13 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
JP2017513844A (ja) 2014-04-23 2017-06-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 知的障害の処置のためのｍＧｌｕ２／３アンタゴニスト
WO2015191630A1 (en) * 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
JP2017206438A (ja) * 2014-08-22 2017-11-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロイミダゾ［１，５−ｄ］［１，４］オキサゼピン化合物（ＴＥＴＲＡＨＹＤＲＯＩＭＩＤＡＺＯ［１，５−ｄ］［１，４］ＯＸＡＺＥＰＩＮＥＣＯＭＰＯＵＮＤ）
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
EP3737362B1 (en) 2018-01-12 2025-10-15 Kdac Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
CN110407740A (zh) * 2019-09-04 2019-11-05 上海毕得医药科技有限公司 一种3-溴-2-乙基吡啶的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052172T3 (es) * 1989-03-23 1994-07-01 Pfizer Agentes antialergicos basados en diazepina.
BR0014859A (pt) 1999-10-15 2002-07-16 Hoffmann La Roche Derivados de benzodiazepina
ATE261945T1 (de) 1999-10-15 2004-04-15 Hoffmann La Roche Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten

Also Published As

Publication number Publication date
HK1078858A1 (zh) 2006-03-24
AR038481A1 (es) 2005-01-19
SI1474416T1 (sl) 2008-02-29
CN1633430A (zh) 2005-06-29
EP1474416B1 (en) 2007-09-26
UY27654A1 (es) 2003-08-29
CA2474219C (en) 2010-04-13
IL163102A (en) 2011-07-31
JP4077411B2 (ja) 2008-04-16
NO20043237L (no) 2004-08-02
US6949542B2 (en) 2005-09-27
MY176608A (en) 2020-08-18
WO2003066623A1 (en) 2003-08-14
RU2315764C2 (ru) 2008-01-27
DE60316538D1 (de) 2007-11-08
CA2474219A1 (en) 2003-08-14
US20030166639A1 (en) 2003-09-04
JP2005522440A (ja) 2005-07-28
DE60316538T2 (de) 2008-08-21
PT1474416E (pt) 2007-12-27
AU2003205695B2 (en) 2008-04-03
ES2294264T3 (es) 2008-04-01
GT200300028A (es) 2004-06-11
KR20040081486A (ko) 2004-09-21
AU2003205695B8 (en) 2008-05-01
EP1474416A1 (en) 2004-11-10
HRP20040678A2 (en) 2005-10-31
PA8565901A1 (es) 2003-09-05
BR0307474A (pt) 2004-11-09
ZA200406032B (en) 2005-10-12
DK1474416T3 (da) 2008-01-14
MXPA04007516A (es) 2004-11-10
AU2003205695A1 (en) 2003-09-02
ATE374196T1 (de) 2007-10-15
TW200302730A (en) 2003-08-16
NO327697B1 (no) 2009-09-14
PL372425A1 (en) 2005-07-25
TWI326599B (en) 2010-07-01
RU2004126945A (ru) 2005-06-27
NZ534122A (en) 2006-12-22
PE20031011A1 (es) 2003-11-29

Similar Documents

Publication Publication Date Title
CN100497333C (zh) 用于治疗神经紊乱的二氢苯并二氮杂-2-酮衍生物
CN106061480B (zh) 治疗性抑制性化合物
CN108884068B (zh) 作为dub抑制剂的1-氰基-吡咯烷衍生物
CN100408564C (zh) 治疗hiv的吡唑衍生物
CN104302634B (zh) 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
CN103842340B (zh) 核转运调节剂及其应用
US12233065B2 (en) Inhibitors of RNA helicase DHX9 and uses thereof
CN103459382B (zh) 用于抑制pask的杂环化合物
CN102892759A (zh) 具有犬尿氨酸产生抑制作用的含氮杂环化合物
CN105143185A (zh) 新的嘧啶和吡啶化合物以及它们的用途
KR20110091550A (ko) 5-ｈｔ2ｂ 수용체 길항활성을 가지는 신규 피라졸-3-카복사미드 유도체
CN101641346A (zh) 作为mglur2拮抗剂的吡啶和嘧啶衍生物
JP2017500333A (ja) グルコース輸送阻害剤
WO2005023782A1 (ja) 置換された縮環ピリミジン－４（３ｈ）－オン化合物
WO2021213476A1 (zh) 一种吡唑并[1,5-a]吡啶类衍生物及其制备方法，组合物以及用途
HK1078858B (en) Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders
CN117430589A (zh) 2-氨基嘧啶类化合物或其盐及其制备方法和用途
HK1230502B (zh) 治疗性抑制性化合物
HK1230502A1 (en) Therapeutic inhibitory compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1078858

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1078858

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090610

Termination date: 20190128